Key Takeaways
- A clean-slate quarter, not a growth quarter: Consolidated PAT fell to ₹45.9 cr from ₹68.6 cr YoY as the holding company swung to a loss and broking revenue declined, while Care Health quietly doubled its H1 profit.
- The legacy cleanup is officially over: RBI lifted the CAP on Religare Finvest in July 2025, all banks removed the fraud classification, and the ₹1,500 cr preferential warrant issue closed, leaving the platform debt-free and fully recapitalized.
- Care Health is the earnings engine: H1 top line grew 19% to ₹5,100 cr, retail grew 28%, and H1 profit more than doubled to ₹177 cr, even after a ₹154 cr accounting headwind from the 1/N change.
- Every subsidiary is now in "plan formulation" mode: RFL, housing finance, and broking are all rebuilding IT systems and leadership teams, but none have disclosed a dated business plan or growth target yet.
- What to watch next quarter: Whether the promised business plans for RFL and housing finance materialize, the pace of leadership hiring, and any concrete step toward the monetization or value-unlocking the Board is evaluating.
The Legacy Cleanup Is Complete
- RBI CAP lifted: The Corrective Action Plan imposed on Religare Finvest in January 2018 was removed in July 2025, and all lender banks removed the fraud classification this year.
- Fraud tag gone: The fraud classification by lenders in 2020, stemming from erstwhile promoter fund diversion, has been fully resolved.
- SME book liquidated: RFL's core SME book has been reduced to roughly ₹95 cr, with all assets converted to cash (approximately ₹423 cr) through focused collection and recovery, achieving roughly 98% collection efficiency.
- No debt, no ALM mismatches: RFL has settled its entire debt, carries no cumulative ALM mismatches up to five years, and holds a CRAR of roughly 198% against a 15% regulatory requirement.
- Governance rebuild: The Board was strengthened by onboarding promoter family nominees, and the company has appointed a new Group General Counsel from Bajaj Finance and a Group CHRO from UTI Mutual Fund.
Pratul Gupta: "We chose reform over rhetoric, and we chose to fix what was broken, structurally or financially."
Care Health: The Standout Performer
- Top-line momentum: H1 FY26 top line grew 19% on an N basis to ₹5,100 cr, with retail business growing 28%; October continued with 22% overall growth and 39% retail growth.
- Profitability surge: H1 profit on an N basis more than doubled to ₹177 cr from ₹83 cr YoY, even after the 1/N accounting change reduced H1 top line by ₹550 cr and profitability by ₹154 cr.
- Combined ratio improving: Q2 combined ratio improved to 100% from 102% YoY; on a 1/N basis, the Q2 combined ratio improved 210 bps versus the preceding quarter.
- Claim ratio stabilizing: Q2 claim ratio was 65% versus 64% YoY, a jump of just 1%; the ratio had risen last year in Q1 due to heat wave and vector-borne claims but is now stabilizing.
- Group business disciplined: Group business growth in H1 was flat because the company chose not to renew some policies in a highly competitive market; management targets a combined ratio below 100 for group and says it is running at that level.
- Investment book growing: The investment book grew by ₹900 cr versus March 2025, driven by business growth and a capital infusion of ₹322 cr in September.
- GST benefit passed through: Care Health passed the ITC benefit on distribution costs to distributors, reducing distribution cost only for retail business; on non-distribution costs, operating leverage from the improving retail business is expected to offset the impact.
Ambrish Jindal: "For this quarter, we don't see any price hike."
The Other Businesses: Cleaning Up, Gearing Up
| Business | Q2 Trend | What Changed |
|---|---|---|
| Religare Broking | ▼ Revenue fell to ₹89.6 cr from ₹110.5 cr YoY; PBT fell to ₹3.3 cr from ₹18 cr | E-governance business demerged to Religare Digital Solutions; technology refresh in the works; targeting industry-plus growth with additional capital |
| Religare Finvest (RFL) | ▼ Core interest income declining as portfolio liquidates; PAT rose to ₹30.8 cr QoQ from ~₹18 cr on provision reversals | Legacy cleanup complete; IT platforms being refurbished; business plan being finalized after a 7-8 year hiatus |
| Religare Housing | ▼ Total revenue dropped slightly as book size shrinks | LOS and LMS systems being upgraded; targeting a four-digit AUM franchise in the next few years with an asset-light hub-and-spoke model focused on Tier 2-4 cities |
- Capital support deployed: ₹25 cr was given to Religare Broking and ₹20 cr to housing finance recently.
- Geographic priority for housing: South (four states except Kerala), then North, then West.
Capital, Structure & the Promoter's Long Game
- ₹1,500 cr warrant issue closed: The promoter group and other marquee investors each participated at ₹750 cr, leaving REL debt-free after it repaid its ₹75 cr loan.
- Board reconstituted: Three Burman family members are expected to join the Board soon, subject to regulatory approvals; the NBFC Board has already been strengthened with a promoter family nominee.
- Corporate structure under evaluation: Management and the Board are evaluating options to add shareholder value, but want to "curate these businesses and make them more resilient and robust" before taking any capital market action.
- Monetization on the horizon, undated: Management is evaluating proposals for monetization or strategic initiatives and will discuss with the Board "at the opportune time when we feel that we can maximize shareholder value."
- Promoter intent: The Burman family views Religare as a significant platform to foray into various financial services within the regulatory framework, with the intent to scale up franchises for larger shareholder value enhancement.
Pratul Gupta: "What we understand from the family and the promoter group is that they are here for long-term growth. This Religare is a platform they identified and they sort of started taking interest many years back which finally culminated into open offer in September 2023 and after slightly delayed process got concluded in February 2025."
What Management Would Not Disclose
- Care Health Q2 on 1/365 basis: Management did not have the numbers handy and said IFRS migration is underway; results may be available next quarter or the quarter after.
- IFRS-based combined ratio: Early trends look better than reported, but management said it is "not the right time to comment more on that."
- Group business combined ratio: Management said it targets below 100 and is running at that level, but did not provide a specific number.
- Long-term product strategy dissection: Management declined to share granular data, stating it "may not be available in the public domain."
- GST benefit net margin impact: Management acknowledged the offset on non-distribution costs from operating leverage but did not quantify the net margin effect.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| RFL business plan | Team finalizing a business plan after a 7-8 year hiatus; will present once ready | No date given |
| NBFC new business plans | Plans being formulated; will be shared when finalized | No date given |
| Housing finance scale-up | Target a four-digit AUM franchise with exponential rise | Next two odd years |
| Broking growth | Industry-plus growth with additional capital and technology refresh | Next few quarters and years |
| Leadership hiring | More experienced business leaders to join across HoldCo and subsidiaries | Next couple of quarters |
| Monetization / strategic initiatives | Evaluating proposals; will act when shareholder value can be maximized | "At the opportune time" |
| Care Health IFRS results | Migrating slowly; results may be available | Next quarter or next to next quarter |
| Care Health pricing | No price hike this quarter; will reevaluate and correct at appropriate time | Undated |
| Lakshmi Vilas Bank deposit recovery | Making all efforts to recover ₹800 cr; believes it has a very good case with DBS as counterparty | No date given |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Total income (consolidated) | ₹2,082 cr, vs ₹1,971 cr in Q2 FY25 |
| Total expenses (consolidated) | ₹2,025 cr, vs ₹1,903.5 cr in Q2 FY25 |
| Profit after tax (consolidated) | ₹45.9 cr, vs ₹68.6 cr in Q2 FY25 |
| Total income (standalone) | ₹7.6 cr, vs ₹22.9 cr in Q2 FY25 |
| Loss (standalone) | ₹4 cr, vs profit of ₹9.4 cr in Q2 FY25 |
| Care Health GWP (FY25 full year) | Over ₹9,200 cr |
| Care Health H1 FY26 top line (N basis) | ₹5,100 cr, growth of 19% YoY |
| Care Health retail business growth (H1 FY26) | 28% |
| Care Health October growth | 22% overall, retail book growing at 39% |
| Care Health H1 FY26 profitability (N basis) | ₹177 cr, vs ₹83 cr in H1 FY25, increase of more than 100% |
| Care Health Q2 FY26 profitability (N basis) | ₹134 cr, vs ₹56 cr in Q2 FY25 |
| Care Health combined ratio Q2 (N basis) | 100%, vs 102% in Q2 FY25 |
| Care Health claim ratio Q2 (N basis) | 65%, vs 64% in Q2 FY25 |
| Care Health claim ratio H1 (N basis) | 68.1%, vs 65.1% in H1 FY25 |
| Care Health solvency ratio | 1.89, against minimum control level of 1.50 |
| Care Health market share (health insurance space) | 9.9% |
| Care Health market share within SAHI | 22% |
| Care Health retail health market share among industry | 11.2% |
| Care Health retail health market share among SAHI | 19.2% |
| Care Health investment book | ₹9,500 cr as on September 2025 |
| Care Health investment yield | 7.2% to 7.3% |
| Care Health price hike on retail portfolio (past 12 months) | 8% to 10% |
| Religare Broking Q2 FY26 top line | ₹89.6 cr, vs ₹110.5 cr in Q2 FY25 |
| Religare Broking Q2 FY26 PBT | ₹3.3 cr, vs ₹18 cr in Q2 FY25 |
| Religare Broking Q2 FY26 profit | ₹2.6 cr, vs ₹13.5 cr in Q2 FY25 |
| Religare Broking active customer base | 2.5 lakh |
| Religare Broking total customer base | 12 lakh |
| RFL Q2 FY26 PAT | ₹30.7 cr, vs ₹1.5 cr in Q2 FY25 |
| RFL H1 FY26 net profit | ₹48.6 cr, vs ₹9.6 cr in H1 FY25 |
| RFL net worth | ~₹812 cr, increased from ₹781.6 cr last quarter |
| RFL CRAR | 197.6%, vs regulatory requirement of 15% |
| RFL net NPA ratio | ~1% |
| RFL collection efficiency | 97% to 98% |
| RFL cash balance | ~₹423 cr |
| RFL core SME book | ~₹95 cr |
| Religare Housing Finance AUM | ~₹245 cr |
| Religare Housing Finance Q2 FY26 revenue | ₹7.41 cr, vs ₹8.43 cr in Q2 FY25 |
| Religare Housing Finance CRAR | 142.4% |
| Religare Housing Finance NNPA | 3.3% |
| Religare Housing Finance collection efficiency | 97.34% |
| Religare Housing Finance yield | ~15% |
| Preferential issue of warrants | ₹1,500 cr total, promoter group ₹750 cr, other investors ₹750 cr |
| Capital infusion in Care Health (September) | ₹322 cr |
| REL capital ploughed into Care rights issue | ₹256 cr |